(Q83470443)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin (English)

1 reference

10.2165/11584350-000000000-00000

Crossref

DOI

https://api.crossref.org/works/10.2165/11584350-000000000-00000

25 November 2024

1 reference

ChEBI release 2020-05-28

1 reference

Li Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Angela Tang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Lorna Castaneda

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

David W. Boulton

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21348538

25 November 2024

Ernst U. Frevert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21348538

25 November 2024

Nimish N. Vachharajani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21348538

25 November 2024

David M. Kornhauser

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21348538

25 November 2024

Chirag G. Patel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21348538

25 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21348538

25 November 2024

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

April 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21348538

Clinical Pharmacokinetics

25 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

253-265

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21348538%20AND%20SRC:MED&resulttype=core&format=json

Effects of liver disease on pharmacokinetics. An update

23 January 2020

cites work

1 reference

12 December 2020

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

12 December 2020

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

1 reference

12 December 2020

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

12 December 2020

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

12 December 2020

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

12 December 2020

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

12 December 2020

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

12 December 2020

Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study

1 reference

12 December 2020

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

1 reference

12 December 2020

Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease

1 reference

12 December 2020

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

13

1 reference

10.2165/11584350-000000000-00000

Crossref

DOI

https://api.crossref.org/works/10.2165/11584350-000000000-00000